Theory Paper IDrNB Cardiology – Theory Notes
MANAGEMENT OF THE FAILING FONTAN CIRCULATION
ITHE FONTAN PHYSIOLOGY AND THE “FAILING FONTAN” DEFINITION
- The Fontan Circulatory Paradox: The Fontan operation (Total Cavopulmonary Connection [TCPC]) routes systemic venous return from the SVC and IVC directly into the pulmonary arterial tree without a subpulmonary ventricular pump. Consequently, the circulation operates under a fundamental physiological paradox: chronic upstream systemic venous hypertension (CVP 12 to 20 mmHg) required to drive passive transpulmonary flow, coupled with chronic downstream systemic ventricular preload deprivation and low cardiac output.
- Definition of the “Failing Fontan”: A multi-organ clinical syndrome of circulatory attrition characterized by progressive decline in functional capacity, refractory systemic venous congestion (ascites, edema), worsening cyanosis, arrhythmias, or lymphatic/end-organ failure (Protein-Losing Enteropathy, Plastic Bronchitis, or Fontan-Associated Liver Disease)—which frequently occurs even when single-ventricle systolic ejection fraction is completely preserved.
IIFOUR DISTINCT HEMODYNAMIC PHENOTYPES OF FONTAN FAILURE (ADAPTED FROM BOOK ET AL.)
- Phenotype I — Reduced Systolic Function (Failing Single Ventricle with Low EF): Classic systolic pump failure, most common when the systemic single ventricle is a morphological Right Ventricle (e.g., Hypoplastic Left Heart Syndrome) subjected to systemic afterload and chronic systemic atrioventricular (tricuspid) valve regurgitation.
- Phenotype II — Preserved Systolic Function with Elevated Ventricular End-Diastolic Pressure (Diastolic / Restrictive Failure): Progressive myocardial hypertrophy, interstitial fibrosis, and loss of ventricular compliance raise systemic ventricular end-diastolic pressure (VEDP greater than 12 to 15 mmHg), which backs up across the lungs to mandate dangerously high Fontan venous pressures.
- Phenotype III — Normal Heart with Elevated Pulmonary Vascular Resistance or Pathway Obstruction (“Pulmonary / Conduit Failure”): Preserved ventricular systolic and diastolic function, but passive flow is blocked by anatomical stenosis in the Fontan conduit/baffle or branch pulmonary arteries, pulmonary vein compression, or maladaptive pulmonary vascular remodeling (elevated PVR) from non-pulsatile flow.
- Phenotype IV — Abnormal Lymphatics with Near-Normal Hemodynamics (“Lymphatic Failure”): Decompression of pressurized thoracic duct and hepatoduodenal lymphatics into low-resistance mucosal lumen spaces, manifesting as Protein-Losing Enteropathy (PLE) or Plastic Bronchitis (PB).
| Failing Fontan Phenotype | CVP / Fontan Pressure | Ventricular EDP (PAWP) | Cardiac Output | Primary Pathophysiological Driver |
|---|---|---|---|---|
| Type I: Systolic Failure | Elevated (>15 mmHg) | Elevated (>12 mmHg) | Low | Morphological RV systolic failure; severe AV valve regurgitation |
| Type II: Diastolic Failure | Elevated (>15 mmHg) | Markedly Elevated (>15 mmHg) | Low / Normal | Stiff, fibrotic non-compliant single ventricle |
| Type III: Fontan / PA Impedance | Markedly Elevated (>18 mmHg) | Normal (<10 mmHg) | Low | Conduit/PA stenosis; elevated PVR (wide transpulmonary gradient >6–8 mmHg) |
| Type IV: Lymphatic Failure | Mild-Moderately Elevated | Normal / Mildly Elevated | Normal / High | Thoracic duct hypertension -> PLE (enteric leak) or Plastic Bronchitis (airway leak) |
IIIDIAGNOSTIC WORKUP (ESC 2020 ACHD / AHA 2019 GUIDELINES)
- Invasive Cardiac Catheterization (Class I Mandatory at Low Threshold): Any Fontan patient presenting with unexplained decline, edema, ascites, PLE, plastic bronchitis, worsening cyanosis, or arrhythmia requires complete right and left heart catheterization:
- Diagnostic Hemodynamic Cut-offs: A mean Fontan/cavopulmonary pressure of 15 mmHg or greater (and especially greater than 18 to 20 mmHg) or a Transpulmonary Gradient (TPG = mean PA pressure minus LA/wedge pressure) greater than 6 to 8 mmHg confirms a failing circuit.
- Zero-Tolerance for Anatomical Gradients: In a passive non-pulsatile circuit, even a 1 to 2 mmHg pressure gradient across the Fontan conduit, Glenn anastomosis, or branch pulmonary arteries represents a severe hemodynamically significant obstruction that mandates percutaneous stenting.
- Collateral Mapping: Identifies venovenous collaterals (from SVC/innominate/IVC to pulmonary veins/LA, causing severe cyanosis) and aortopulmonary collaterals (APCs) (causing competitive pulmonary flow and single-ventricle volume overload).
- Cross-Sectional Imaging (CMR and MDCTA): CMR quantifies single-ventricle volumes, ejection fraction, AV valve regurgitant fraction, collateral flow fraction, and T2-weighted Dynamic Contrast MR Lymphangiography (mapping thoracic duct leak pathways); MDCTA evaluates stents, conduit thrombus, and pulmonary embolism.
- End-Organ Biomarkers and Liver Surveillance: Serum Albumin, Total Protein, IgG, lymphocyte count, and Fecal Alpha-1 Antitrypsin clearance (for PLE); NT-proBNP; and annual FALD surveillance (LFTs, GGT, Platelet count, Alpha-Fetoprotein [AFP], and Liver Ultrasound / Transient Elastography [FibroScan]).
IVMECHANISM-SPECIFIC MANAGEMENT STRATEGIES (ESC 2020 / AHA 2019)
AHemodynamic and Pharmacological Optimization
- Judicious Diuretic Therapy: Loop diuretics (Furosemide/Torsemide) combined with Mineralocorticoid Receptor Antagonists (Spironolactone 25 to 100 mg/day) are the cornerstone for controlling ascites and peripheral edema; however, over-diuresis must be avoided because excessive reduction in central venous pressure abolishes the passive transpulmonary gradient and precipitates acute low cardiac output and prerenal azotemia.
- Pulmonary Vasodilators (Lowering the “Critical Bottleneck” PVR — Class IIb in ESC 2020): Because pulmonary vascular resistance is the primary determinant of single-ventricle preload in a Fontan circuit, PDE-5 Inhibitors (Sildenafil, Tadalafil, or Udenafil [studied in the Phase III FUEL Trial, 2020]) and Endothelin Receptor Antagonists (Bosentan [TEMPO Trial] or Macitentan) are used to lower PVR and improve submaximal exercise capacity in patients with elevated Fontan pressures and low PAWP.
- Systemic Ventricular GDMT: While empirical ACE inhibitors showed no benefit in single-ventricle and preserved-EF Fontan cohorts (e.g., the Pediatric Heart Network infant single-ventricle enalapril trial), ACEi/ARBs/ARNI, Beta-blockers, MRAs, and SGLT2 Inhibitors (Empagliflozin/Dapagliflozin) are utilized in Phenotype I (systolic dysfunction).
BTargeted Management of Lymphatic Failure (PLE and Plastic Bronchitis)
- Medical Therapy for Protein-Losing Enteropathy (PLE):
- Dietary Modification: High-protein (greater than 2 g/kg/day), low-long-chain-fat, high-Medium-Chain Triglyceride (MCT) diet (because MCTs are absorbed directly into the portal venous bloodstream rather than intestinal lacteal lymphatics, bypassing and decompressing engorged gut lymphatics).
- Targeted Anti-Inflammatory and Endothelial Therapy: Oral Controlled-Ileal-Release Budesonide (3 to 9 mg/day) suppresses enteric mucosal inflammation and restores tight-junction integrity (requires monitoring for systemic cushingoid effects because hepatic congestion impairs first-pass steroid metabolism); High-Dose Spironolactone; Subcutaneous Unfractionated Heparin (which restores enterocyte membrane heparan sulfate proteoglycans); Octreotide (reduces splanchnic blood and lymphatic flow); and intravenous Albumin + Furosemide infusions with IVIG replacement for severe hypogammaglobulinemia.
- Acute and Chronic Management of Plastic Bronchitis (PB):
- Airway Cast Clearance: Nebulized Recombinant Tissue Plasminogen Activator (tPA / Alteplase) (which lyses the fibrin matrix of bronchial casts), nebulized heparin, dornase alfa, hypertonic saline, vest physiotherapy, and urgent rigid/flexible bronchoscopic cast extraction for airway obstruction.
- Interventional Lymphatic Decompression (Game-Changer for PLE & PB):
- Percutaneous Lymphatic Embolization: Using intranodal/intrahepatic lymphangiography and thoracic duct cannulation to selectively embolize abnormal peribronchial lymphatic leaks (in Plastic Bronchitis, >85% resolution) or hepatoduodenal/periduodenal lymphatic fistulae (in PLE) using lipiodol, cyanoacrylate glue, and microcoils.
- Innominate Vein Turn-Down (Hraska Procedure): Surgically disconnecting the thoracic duct-draining left innominate vein from the high-pressure SVC/Glenn and anastomosing it directly to the low-pressure pulmonary venous atrium, decompressing the thoracic duct from 18 mmHg down to 6 mmHg.
CCatheter and Surgical Structural Rescue
- Relief of Pathway Obstruction (Class I): Balloon angioplasty and endovascular stenting of any Fontan conduit, baffle, or branch pulmonary artery stenosis, and coil embolization of large aortopulmonary collaterals.
- Creation or Enlargement of a Fontan Fenestration (Class IIa/IIb): Transcatheter needle puncture and stenting to create a 4 to 6 mm fenestration between the Fontan conduit and the systemic atrium decompresses CVP (improving PLE/PB) and increases cardiac output at the cost of mild cyanosis. (Conversely, if severe cyanosis is driven by large venovenous collaterals, transcatheter coil/plug occlusion restores saturation provided baseline Fontan pressure is not prohibitively high.)
- Arrhythmia Control and Surgical Fontan Conversion: Immediate DC cardioversion and 3D catheter ablation for Intra-Atrial Reentrant Tachycardia (IART). Patients with an obsolete dilated Atriopulmonary Fontan, refractory IART, and preserved ventricular function undergo Surgical Fontan Conversion to an Extracardiac TCPC + Right Atrial Reduction + bi-atrial Cryo-Maze + epicardial dual-chamber pacemaker.
VDEFINITIVE THERAPY: MECHANICAL SUPPORT AND TRANSPLANTATION
- Indications for Heart (or Combined Heart-Liver) Transplantation: Refractory PLE or Plastic Bronchitis (which resolves completely in over 90 percent of patients once normal low-CVP biventricular physiology is restored by transplant), end-stage systemic ventricular failure, or uncorrectable Fontan hemodynamic failure.
- Unique Transplant Challenges: High surgical bleeding risk from multiple redo sternotomies and high-pressure collateral vessels, need for extensive pulmonary artery and vena caval reconstruction, high HLA allosensitization (from prior homograft patches and transfusions), and determining when advanced FALD cirrhosis mandates en-bloc Combined Heart-Liver Transplantation (CHLT) rather than isolated heart transplantation.
VIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT
- Mandatory Annual FALD FibroScan and AFP Screening: Because many Indian Fontan survivors were operated at an older childhood age (resulting in longer cumulative pre- and post-Fontan hepatic injury), annual Transient Elastography (FibroScan), liver ultrasound, and serum Alpha-Fetoprotein (AFP) are essential to detect early cardiac cirrhosis and hepatocellular carcinoma.
- Maximizing Native Fontan Survival: Given the limited availability and high cost of ACHD Heart and Heart-Liver Transplantation in India, aggressive medical and transcatheter palliation—combining Sildenafil + Spironolactone + MCT diet + oral Budesonide, stenting of minor branch PA stenoses, and transcatheter fenestration creation—is the frontline strategy.
- Nutritional Rehabilitation and Contraceptive Counseling: In Indian children and young adults with PLE, correcting severe protein-calorie malnutrition, fat-soluble vitamin deficiencies (A, D, E, K), and hypocalcemia is critical, alongside proactive counseling against high-risk pregnancy (mWHO Class IV in any failing Fontan).
Key references
- Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
- Rychik J, Atz AM, Celermajer DS, et al.: Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association, Circulation, 2019.
- Book WM, Gerardin JF, Saraf AP, Marie Valente A, Rodriguez FH III: Clinical Phenotypes of Fontan Failure: Implications for Management, Congenital Heart Disease, 2016.
- Goldberg DJ, Zak V, Goldstein BH, et al. (FUEL Investigators): Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, Circulation, 2020.
meritmedscript.comDr. Sidhartha Mullapudi
